Stocks-NBIX-Neurocrine Biosciences Inc

NBIX Neurocrine Biosciences Inc

120.17 -1.04 (-0.86%)
Market ClosedDelayed Prices By NASDAQ, in USD
Trade
Stocks-NBIX-Neurocrine Biosciences Inc
NBIX Neurocrine Biosciences Inc
Trade

Neurocrine Biosciences Inc price

-5.59% Past Week
Created with Highcharts 4.2.7 /Highstock 4.2.7
Market Cap
12.13B
Day’s Range
119.64
-
121.99
52W Range
103.38
-
156.73
Volume (3M)
887.32K
Price-Earnings Ratio
36.3
Revenue
2.12B

Neurocrine Biosciences Inc Latest News

View All
Why Neurocrine Biosciences (NBIX) Stock is Moving TodayWhy Neurocrine Biosciences (NBIX) Stock is Moving TodayGuruFocus9 days agoWhy Neurocrine Biosciences Stock Was Tumbling This WeekWhy Neurocrine Biosciences Stock Was Tumbling This WeekThe Motley Fool10 days agoNeurocrine’s Schizophrenia Drug Excels in Phase 2 TrialsNeurocrine’s Schizophrenia Drug Excels in Phase 2 TrialsTipRanks12 days ago
Top Discussions
AlessioBot
Italy
5 days ago
Like CommentShare
null
.
Jurrsiz
Netherlands
9 days ago
$NBIX (Neurocrine Biosciences Inc) After last week's 18% share price decline to US$124, the stock trades at a forward P/E ratio of 23x. Average trailing P/E is 24x in the Biotechs industry in the US. May be a good moment to buy some shares🤔 Total returns to shareholders of 29% over the past three... Show More
Like CommentShare
null
.
AndersEgsvang
Denmark
9 days ago
This week, the market has had a keen focus on $NVDA (NVIDIA Corporation) one of the largest stocks globally and a pioneer in artificial intelligence (AI). Nvidia released an impressive earnings report that actually exceeded expectations on revenue. However, the stock dropped by 6% on the day of the... Show More
Like CommentShare
null
.
Rofman
Spain
11 days ago
Edited
🟢Cómo es que algunos inversores logran superar consistentemente al mercado durante décadas mientras otros fracasan❓ 🟢Qué estrategias comunes comparten estos gigantes de la inversión que podrías aplicar hoy mismo a tu cartera❓ 🟢Qué lecciones cruciales podemos aprender de la trayectoria de estos titanes... Show More Translate
Like CommentShare
1 reply
null
.
BrajeshOfficial
France
11 days ago
🆂🆃🅾🅲🅺🆂 🅾🅵 🆃🅷🅴 🅳🅰🆈: 𝗕𝘂𝘆 $LUXH (Luxurban Hotels Inc) >> 35%+ $EJH (E-Home Household Service) >> 20%+ 𝗦𝗼𝗹𝗱 $NBIX (Neurocrine Biosciences Inc) >> -15%+ $NCNO (nCino Inc.) >> -10%+ 𝗠𝗮𝗿𝗸𝗲𝘁: -Ve & +Ve (MIX) 𝗧𝗼𝗽 𝗛𝗲𝗮𝗱𝗹𝗶𝗻𝗲𝘀: >> Warren Buffett... Show More
Like CommentShare
3 replies
null
.
AndersEgsvang
Denmark
14 days ago
💚 + 25,9% past 9 months 💚 +270 followers 9 months ago I opened my account here on eToro, after trading for more than 12 years on other platforms. As a popular investor on eToro, I’m committed to maintain a portfolio that optimizes growth and profitability. My strategy is to invest in companies that... Show More
Like CommentShare
null
.
Diabetes-Med
United Kingdom
3 days ago
Dear Investors, Here is your monthly update for August 2024 ✨ August 2024 started with extreme volatility in global markets, with fears of a hard landing in the US economy and the expectancy of bigger rate cuts. During the month, markets recovered most of the losses, leading to a powerfull rally in... Show More
Like CommentShare
TheMightyBuy
United Kingdom
11 days ago
undefined logo
NBIX
Neurocrine Biosciences Inc
120.03
-1.04 (-0.86%)
Trade
Like CommentShare
GSKZ22
Italy
2 months ago
📢 📆 2024 - Week 28 📈 profits from closed trades 🟢 0️⃣.1️⃣2️⃣% of the total amount invested: 🔝3 in terms of % profits on investment 🥉 $NBIX (Neurocrine Biosciences Inc) 🥈 $ENPH (Enphase Energy Inc.) 🥇 $AEM (Agnico Eagle Mines Ltd) 🔝3 in terms of 💰 made 🥉 $NBIX 🥈 $ENPH 🥇 $AEM
Like CommentShare

About Neurocrine Biosciences Inc

Neurocrine Biosciences Inc is an American biopharmaceutical company headquartered in San Diego, California. Operating globally, the firm was founded in 1992 and has a focus on neuroscience. It is primarily engaged in the discovery, development, and commercialisation of a range of life-changing treatments for patients with serious and under-addressed neurological and endocrine-related diseases and psychiatric disorders. The company develops drugs for women’s health issues such as endometriosis, uterine fibroids, and polycystic ovary syndrome. It is also involved in drug discovery for neurological diseases such as Parkinson’s disease and tardive dyskinesia, as well as for other disorders ranging from anxiety, depression, and anhedonia to epilepsy, schizophrenia, and congenital adrenal hyperplasia (CAH). Neurocrine Biosciences Inc specialises in the targeting and interruption of disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. Commercial products available from Neurocrine Biosciences include Ingrezza, used to treat adult patients with tardive dyskinesia (TD), and Ongentys, a medicine used with levodopa and carbidopa in people with Parkinson’s disease (PD). The firm’s stock is listed on the Nasdaq Global Select Market, where it trades under the stock ticker NBIX. Add Neurocrine Biosciences Inc to your eToro watchlist to start monitoring NBIX price movements and receive real-time updates.
Kevin Charles Gorman, PhD, MBA
CEO
1.4K
Employees
1992
Founded
San Diego, California, US
HQ
Show More
Med TechNASDAQ

ESG: A New Source of Insight

What is an ESG Score?
This number is a measure of a company’s exposure to environmental, social, and governance risks. Influencing factors include energy efficiency, safety, social policies, and more. Learn More
Powered by ESG Book
Get insight into a company's sustainability using ESG (environmental, social, and governance) scores.
0
100
49
Medium
Industry 
Avg. 46 
52
Environment
48
Social
52
Governance

Analyst Forecast

Consensus
Strong Buy
Price Target
172.18
Based on 14 analysts who covered NBIX 

People Also Bought